ArticlePharmacoEconomics2022
An EQ-5D-Y-3L Value Set for Belgium.
Article in PharmacoEconomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Measurement Properties of the EQ-5D Instruments in Children and Adolescents: A Systematic Review.Applied health economics and health policy · 2025Pooled it
- The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review.PharmacoEconomics · 2025Pooled it
- The Influence of Perspective on the Valuation of the EQ-5D-Y-3L: A Comparison Using the OPUF Tool and a Discrete Choice Experiment.PharmacoEconomics · 2026Trial
- Justifying and Classifying Adults' Roles in Child Health State Valuation: A Novel Taxonomy.PharmacoEconomics · 2026Review
- Do EQ-5D-Y-3L value sets have common properties, and how do they compare to EQ-5D-5L value sets?The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Value set of EQ-5D-Y-3L for Hong Kong.Health and quality of life outcomes · 2026Article
- An Australian Value Set for the EQ-5D-Y-3L.Health and quality of life outcomes · 2025Article
- Comparison of EQ-5D-Y-3L Utility Scores Using Nine Country-Specific Value Sets in Chinese Adolescents.PharmacoEconomics · 2025Article
- Modernizing Newborn Screening in the Genomic Era: Importance of Health-Related Quality of Life.PharmacoEconomics - open · 2024Article
- Prognostic model development for risk of curve progression in adolescent idiopathic scoliosis: a prospective cohort study of 127 patients.Acta orthopaedica · 2024Article
- Estimating an EQ-5D-Y-3L Value Set for Brazil.PharmacoEconomics · 2024Article
- Understanding Canadian stakeholders' views on measuring and valuing health for children and adolescents: a qualitative study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Article
- The RETRIEVE Checklist for Studies Reporting the Elicitation of Stated Preferences for Child Health-Related Quality of Life.PharmacoEconomics · 2024Article
- Using Age-Specific Values for Pediatric HRQoL in Cost-Effectiveness Analysis: Is There a Problem to Be Solved? If So, How?PharmacoEconomics · 2023Article
- EQ-5D-Y-3L Value Sets, Valuation Methods and Conceptual Questions.PharmacoEconomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Belgium, a value set for children and adolescents for a generic health-related quality-of-life measure is not available. To inform drug pricing and make resource allocation decisions for children and adolescents, national tax-payers' preferences for youth health states should be known.
objectiveWe aimed to obtain a value set for EQ-5D-Y-3L in Belgium, following the international youth valuation protocol for data collection.
methodsComposite Time Trade-Off interviews were conducted in a sample of 200 adults, either face to face or via video conferencing. Another sample of 1000 adults completed an online discrete choice experiment survey. All adults were asked to take the perspective of a 10-year-old child for both methods. Both samples were representative for Belgium in terms of age, sex and region. A latent class analysis was selected to obtain the relative importance of the five dimensions and their levels based on the discrete choice experiment data, which were anchored with the composite Time Trade-Off censored value for the worst health state (33333).
resultsPreferences from Belgian adults revealed a mean censored value for 33333 for children and adolescents of - 0.475. All the estimated coefficients of the model with 4 latent classes were statistically significant and showed higher disutility as severity levels increase. The most important health dimension was pain/discomfort, followed by feeling sad/worried/unhappy.
conclusionsThis study presents the Belgian EQ-5D-Y-3L value set, which will be included in the Belgian pharmacoeconomic guidelines. The value set enables the calculation of quality-adjusted life-years in children and adolescents, allowing a cost-effectiveness evaluation of health technologies and their youth-specific price setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.